USA - NASDAQ:VANI - US92854B1098 - Common Stock
The current stock price of VANI is 1.5 USD. In the past month the price increased by 8.33%. In the past year, price increased by 9.16%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.73 | 223.47B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.4 | 204.96B | ||
| BSX | BOSTON SCIENTIFIC CORP | 35.24 | 154.03B | ||
| SYK | STRYKER CORP | 28.11 | 141.56B | ||
| IDXX | IDEXX LABORATORIES INC | 56.73 | 57.23B | ||
| BDX | BECTON DICKINSON AND CO | 13.3 | 54.99B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.29 | 50.23B | ||
| RMD | RESMED INC | 25.6 | 36.99B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.21 | 33.96B | ||
| PODD | INSULET CORP | 73.67 | 23.70B | ||
| DXCM | DEXCOM INC | 32.03 | 23.36B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.1 | 17.78B |
Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
VIVANI MEDICAL INC
1350 S. Loop Road
Alameda CALIFORNIA US
Employees: 37
Phone: 14155068462
Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.
The current stock price of VANI is 1.5 USD. The price increased by 4.9% in the last trading session.
VANI does not pay a dividend.
VANI has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
VIVANI MEDICAL INC (VANI) has a market capitalization of 88.86M USD. This makes VANI a Micro Cap stock.
VIVANI MEDICAL INC (VANI) will report earnings on 2025-11-18.
You can find the ownership structure of VIVANI MEDICAL INC (VANI) on the Ownership tab.
ChartMill assigns a technical rating of 7 / 10 to VANI. When comparing the yearly performance of all stocks, VANI is one of the better performing stocks in the market, outperforming 72.13% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to VANI. The financial health of VANI is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months VANI reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS increased by 4.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -88.35% | ||
| ROE | -520.1% | ||
| Debt/Equity | 0 |
8 analysts have analysed VANI and the average price target is 5.1 USD. This implies a price increase of 240% is expected in the next year compared to the current price of 1.5.